It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR T cell therapies in ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...
A new generation of automated technologies in cell and gene therapy manufacturing systems will help more people benefit according to research identifying high production cost as the main impediment to ...
AI automation, and more skilled staff are needed to ensure cancer patients can access potentially life-saving CAR T therapies.
MaxCyte and Ori Biotech Forge Strategic Partnership to Enhance Cell Therapy Manufacturing Efficiency
MaxCyte, Inc. and Oribiotech Ltd. have announced a strategic collaboration to improve efficiency and scalability in cell therapy manufacturing. This partnership will integrate MaxCyte's ExPERT™ ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results